# US 2024/0317732 A1 · A new molecular scaffold for targeting hrpn13

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0317732 A1
- Document ID: US20240317732A1
- Status: Published application
- Kind: A1
- Application number: 18/262,941
- Filed: 2022-01-28
- Published: 2024-09-26
- Earliest claimed: 2021-01-29
- Assignees: The United States of America as represented by the Secretary, Department of Health and Human Service
- Applicants: The United States of America AS Represented By the Secretary, Department of Health and Human Service
- Inventors: Kylie J. Walters; Xiuxiu LU; Nadya I. Tarasova; Eric Rolf SWENSON; Venkatareddy SABBASANI; Beverly Ann MOCK; Snehal GAIKWAD; Deborah CITRIN; Monika CHANDRAVANSHI
- Web page: https://patentgrep.com/patent/US20240317732A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C07C 255/44: at least one of the singly-bound nitrogen atoms being acylated
- C07C 311/46: Y being a hydrogen or a carbon atom
- C07D 209/34: in position 2
- C07D 213/81: Amides; Imides
- C07D 215/227: only one oxygen atom which is attached in position 2
- C07D 217/24: Oxygen atoms
- C07D 277/34: Oxygen atoms
- C07D 279/16: condensed with one six-membered ring
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 513/04: Ortho-condensed systems
- C07K 5/06034: {the side chain containing 2 to 4 carbon atoms}
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules having anti-hRPN13 activity, proteolysis targeting chimeras (PROTACs) incorporating the same, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers involving aberrant hRpn13 activity and/or the presence of hRpn13-Pru/hRpn13 or variants thereof using the same.

## Claims

### Claim 1

A compound comprising a structure of Formula I:
wherein A, B, and C independently comprise an aryl or heteroaryl ring having 5-10 members;
wherein X and Y independently comprise carbon, oxygen, nitrogen, sulfur, a carbonyl group, or a sulfonyl group;
wherein each instance of R6 and R7 is absent or independently comprises hydrogen, halogen, hydroxyl, trifluoromethyl, C1-C6 alkylamino, C1-C6 alkoxy, substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted phenyl group, or Formula II;
wherein L comprises a linker moiety;
wherein E comprises an E3 ubiquitin ligase targeting moiety, a bridging molecule to a ubiquitin E3 ligase complex, an E2 ubiquitin conjugating enzyme targeting molecule, an autophagy-targeting chimera, or a proteasome subunit targeting molecule;
wherein when at least one R7 is present, d is 1 or 2; and
wherein when at least one R6 is present, e is 1 or 2;
wherein R1 comprises —SO2NH2, a carboxylic acid group, fluorine, a trifluoromethyl group, or a tetrazole;
wherein each instance of R2 independently comprises hydrogen, halogen, hydroxyl, trifluoromethyl, C1-C6 alkylamino, C1-C6 alkoxy, or substituted or unsubstituted C1-C6 alkyl, and a is from 1 to 4;
wherein R3 comprises a cyano group, —S(═O)2—R4, —C(═O)—R4, —C(═O)—OR4, —C(═O)—N—R4,R4′, or —S(═O)2—NH2;
wherein R4 and R4′ comprise hydrogen, halogen, hydroxyl, trifluoromethyl, C1-C6 alkylamino, C1-C6 alkoxy, substituted or unsubstituted C1-C6 alkyl, or a substituted or unsubstituted phenyl group;
wherein each instance of R6 independently comprises hydrogen, halogen, hydroxyl, trifluoromethyl, C1-C6 alkylamino, C1-C6 alkoxy, substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted phenyl group, or Formula II, and wherein b is from 1 to 5;
wherein each instance of Ra independently comprises hydrogen, halogen, hydroxyl, trifluoromethyl, C1-C6 alkylamino, C1-C6 alkoxy, or substituted or unsubstituted C1-C6 alkyl; and wherein c is from 1 to 5; and
wherein R9 comprises hydrogen, halogen, hydroxyl, trifluoromethyl, substituted or unsubstituted C1-C6 alkylamino, substituted or unsubstituted C1-C6 alkyl, an azide group, or Formula II;
wherein Z comprises a carbonyl group or a sulfonyl group;
wherein W comprises carbon, oxygen, nitrogen, or sulfur;
wherein each instance of R10 is absent or independently comprises hydrogen, halogen, hydroxyl, trifluoromethyl, C1-C6 alkylamino, a substituted or unsubstituted phenyl group, or Formula II; and wherein f is from 0 to 2; and
wherein the compound is not XL5 and is not XL23.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound comprises Formula Ia, Formula Ib, or any combination thereof:

### Claim 3 (depends on 1)

The compound of claim 1, wherein A and B are independently a substituted or unsubstituted phenyl group.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein C is a substituted or unsubstituted phenyl or pyridyl group.

### Claim 6 (depends on 1)

The compound of claim 1, wherein X is nitrogen.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R7 is hydrogen and d is 1.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Y is a carbonyl group and R6 is absent.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 is —SO2NH2 or a carboxylic acid group.

### Claim 10 (depends on 1)

The compound of claim 1, wherein each R2 is independently hydrogen, trifluoromethyl, methylamino, or methoxy, and wherein a is 4.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R3 is cyano.

### Claim 12 (depends on 1)

The compound of claim 1, wherein each R5 is independently hydrogen, trifluoromethyl, or methylamino and wherein b is 4.

### Claim 13 (depends on 1)

The compound of claim 1, wherein each Ra is independently chloro, hydrogen, or hydroxyl, and wherein c is 4.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R9 is hydrogen, methyl, methylamino, trifluoromethyl, —NHCH2COOH, or Formula II.

### Claim 15 (depends on 1)

The compound of claim 1, wherein at least one of R5, R6, R7, or R9 comprises Formula II and wherein L comprises:
wherein Q comprises a triazole, an amide, a C1-C4 alkyl amide, a sulfonamide, or substituted or unsubstituted spirocyclic rings;
and wherein Z comprises an alkyl group, an alkylene group, a polyether group, or any combination thereof.

### Claim 16 (depends on 15)

The compound of claim 15, wherein Z comprises:
wherein n is 2 or 3 and wherein m is from 1 to 10; or
wherein o is from 0 to 10.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R9 is Formula II and wherein L is:
and wherein Z is an alkyl group, an alkylene group, a polyether group, or any combination thereof.

### Claim 18 (depends on 1)

The compound of claim 1, wherein R9 is Formula II and wherein L is:
wherein q is 0 or 1;
and wherein Z is an alkyl group, an alkylene group, a polyether group, or any combination thereof.

### Claim 19 (depends on 1)

The compound of claim 1, wherein R9 is Formula II and wherein L is:
and wherein r is from 1 to 5.

### Claim at position 20

20-27. (canceled)

### Claim 28 (depends on 1)

The compound of claim 1 having a structure represented by a formula:

### Claim 29 (depends on 1)

The compound of claim 1, having a structure represented by a formula:

### Claim at position 23

30-58. (canceled)
